Acrivon Therapeutics(ACRV) - 2025 Q1 - Quarterly Results

Financial Performance - Acrivon reported a net loss of $19.7 million for Q1 2025, compared to a net loss of $16.5 million in Q1 2024, reflecting an increase in operational expenses[5]. - Research and development expenses increased to $15.4 million in Q1 2025 from $11.5 million in Q1 2024, primarily due to ongoing clinical trials for ACR-368 and ACR-2316[6]. - As of March 31, 2025, Acrivon had cash, cash equivalents, and marketable securities totaling $164.8 million, expected to fund operations into Q2 2027[7]. Clinical Trials and Drug Development - The confirmed overall response rate (cORR) for ACR-368 in OncoSignature-positive patients was 35%, with a disease control rate (DCR) of 80%[4]. - For patients who relapsed after prior therapy, the cORR for ACR-368 was 50%, with a median duration of response (mDOR) not yet reached, exceeding 10 months[4]. - ACR-2316 demonstrated approximately 25% tumor shrinkage in a patient after six weeks of treatment at dose level 3, indicating potential for monotherapy activity[3]. - The company advanced to dose level 4 in the Phase 1 trial of ACR-2316, with no safety concerns reported at previous dose levels[4]. - Upcoming milestones include updates on the registrational trial for ACR-368 and initial clinical data from the Phase 1 study of ACR-2316 in the second half of 2025[10]. Leadership and Strategic Initiatives - Acrivon appointed Dr. Mansoor Raza Mirza as Chief Medical Officer, bringing extensive experience in leading registrational trials in oncology[4]. - The company is leveraging its Generative Phosphoproteomics AP3 platform to enhance drug discovery capabilities and streamline development processes[8].